Doctors advise against off-label use of new Alzheimer s medicine for cerebral amyloid angiopathy
A novel therapy recently approved by the U.S. Food and Drug Administration for patients with Alzheimer s disease amid considerable controversy should not be prescribed by physicians off-label for cerebral amyloid angiopathy (CAA), a similar cerebrovascular condition, according to Steven Greenberg, MD, PhD, director of the Hemorrhagic Stroke Research Program at Massachusetts General Hospital (MGH) and president of the International Cerebral Amyloid Angiopathy Association (ICAAA).
In a letter published in
The Lancet Neurology, Greenberg and eight other officers of the association wrote that there is no clinical evidence that the monoclonal antibody aducanumab is beneficial to patients with CAA, a condition in which proteins known as amyloid corrode arterial walls in the brain and can lead to bleeding and stroke.
Study reveals source of remarkable memory of
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Doctors warn against off-label use of new Alzheimer s drug for cerebral amyloid angiopathy
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
INDIA New England News
The Harvard Gazette
For patients who have experienced certain common types of stroke, a small chip inserted under the skin may help physicians predict their likelihood of experiencing a second stroke, and therefore their likelihood of benefiting from preventive therapy. The findings come from a recent clinical trial published in the Journal of the American Medical Association and led by investigators at Harvard-affiliated Massachusetts General Hospital (MGH) and Northwestern University Feinberg School of Medicine.
Each year, approximately 800,000 strokes occur in the United States, and as many as one-fourth occur in people who experienced a previous stroke. Investigators have been searching for ways to identify patients who are likely to experience a recurrent stroke, as these individuals could be candidates for taking certain medications such as blood thinners. One group of patients who face an elevated risk of recurrent strokes are those wit